Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

X
Trial Profile

A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzalutamide (Primary) ; Pembrolizumab (Primary) ; ZEN 3694 (Primary)
  • Indications Adenocarcinoma; Neuroendocrine carcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Apr 2024 Planned End Date changed from 31 Dec 2025 to 30 Apr 2027.
    • 25 Apr 2024 Planned primary completion date changed from 31 Dec 2025 to 30 Apr 2027.
    • 13 Sep 2022 Interim results (n=22) assessing safety and efficacy ZEN-3694, enzalutamide, and pembrolizumab in metastatic castration resistant prostate cancer patients, presented at the 47th European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top